Are hormonal agents better than chemo in metastatic castration-resistant prostate cancer?

Simple item page
dc.contributor.authorYildirim S.
dc.contributor.authorErdoğan A.P.
dc.date.accessioned2024-07-22T08:06:41Z
dc.date.available2024-07-22T08:06:41Z
dc.date.issued2021
dc.description.abstractOBJECTIVE In this study, we aim to determine which treatment is more appropriate in castration-resistant chemo-therapy-naive patients. Therefore, docetaxel and agents active in the androgen pathway (abiraterone and enzalutamide) were compared retrospectively in patients progressing on androgen deprivation therapy. METHODS The study was designed as a retrospective and multicenter study. Patients from five centers in Turkey were included in the study. The primary endpoint of the study was overall survival (OS) and the second-ary endpoint was progression-free survival. RESULTS Median OS of the docetaxel group was 18.66 months, it was 16.26 months in the hormonal treatment group. There was no statistically significant difference between the groups (p=0.311). Median progression-free survival of the chemotherapy group was 5.6 months, while it was 9 months in the hormonal therapy group. There was statistically significant difference between the groups (p=0.024). CONCLUSION There was statistical difference in progression-free survival in favor of hormonal therapies in our study. The difference did not reflect on OS and there was no difference between hormonal therapies and docetaxel. Heterogeneity in the selection of patients is considered to lead to this result; however, larger randomized controlled studies are needed to determine the most appropriate treatment in these patients. © 2021, Turkish Society for Radiation Oncology.
dc.identifier.DOI-ID10.5505/tjo.2021.2794
dc.identifier.issn13007467
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13658
dc.language.isoEnglish
dc.publisherIstanbul Tip Fakultesi
dc.rightsAll Open Access; Gold Open Access
dc.subjectabiraterone
dc.subjectdocetaxel
dc.subjectenzalutamide
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectcancer chemotherapy
dc.subjectcancer hormone therapy
dc.subjectcontrolled study
dc.subjectdisease burden
dc.subjectfemale
dc.subjectfollow up
dc.subjectGleason score
dc.subjecthuman
dc.subjectmale
dc.subjectmetastatic castration resistant prostate cancer
dc.subjectoverall survival
dc.subjectprogression free survival
dc.subjectretrospective study
dc.titleAre hormonal agents better than chemo in metastatic castration-resistant prostate cancer?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu